the reviewer was that the broken bonds on the surface of calcite may reform quickly to form metastable aragonite, but further research is required to test this hypothesis." "This is an important new mechanism for hydrogen production," says Christopher McKay, senior planetary scientist at the NASA Ames Research Center at Moffett Field, Calif. "Waterwater reactions producing hydrogen are usually associated with high-temperature systems, and it has been thought that they could not operate at low temperatures. This shows how hydrogen can be produced in an ice-covered system and has huge implications for ice-sealed Antarctic ecosystems such as Lake Vida and for the ice-covered ocean moons of the outer Solar System, Europa and Enceladus." 
Barry E. DiGregorio is a freelance writer in Middleport, N.Y.

RESEARCH ADVANCES
Therapeutic Potential of CRISPR Research Raising Safety and Ethics Questions
Marcia Stone CRISPR/Cas9-based genome editing is a potential treatment for Duchenne muscular dystrophy (DMD), according to Charles Gersbach from Duke University in Durham, N.C., and his collaborators there and elsewhere. However, at this stage, that editing is directed to an exon 23 deletion in the mdx model of the disease in mice, with CRISPR/Cas 9-based editing changing "expression of a modifıed dystrophin gene in place of the defective one, [leading to] partial recovery of functional dystrophin protein in skeletal and cardiac muscle, improvement of muscle biochemistry, and signifıcant enhancement of muscle force," they report. "This is the fırst time CRISPR has been successfully delivered throughout the body with a translational approach to treat grown animals with genetic diseases," points out Christopher Nelson, the lead author of their report that appeared 31 December 2015 in Science (doi:10.1126/science.aad5143).
DMD, among the most common fatal genetic diseases of humans, leads to an early death for 1 in every 5,000 newborn males. Gene therapy is promising, but the very large size of the cloned dystrophin gene is a daunting challenge to its further development for clinical use; thus the excitement over a seemingly easier-to-use alternative approach.
CRISPRs, short for "clustered regularly interspaced palindromic repeats," and the "CRISPR-associated protein," known as "Cas," are an ancient form of innate immunity used by many archaea and bacteria to recognize the DNA of invading phage and plasmids, cut them apart, and save the pieces to confer lasting protection. The engineered version of this system can also cleave unwanted genes from a host genome, as it does with faulty DMD exon 23, allowing expression of a more functional replacement.
The dystrophin gene-targeting CRISPR/Cas 9 system was delivered to mice by means of an adeno-associated virus, according to Gersbach, Nelson, and their collaborators. "Collectively, our molecular analyses validated the CRISPR-induced restoration to nearfull-length dystrophin protein levels above the established benchmarks for functional recovery and therapeutic benefıt," says Gersbach, who notes that two other papers in the same issue of Science reported similar results. "We are targeting only somatic muscle tissues in developed mice." Such somatic changes are not heritable.
For now, targeting human germline genes with CRISPRs is prohibited-at least in the United States (US) and Europe. However, an announcement in April 2015 by Chinese researchers that they had modifıed the genomes of nonviable human embryos with CRISPR/ Cas9 led researchers from the US, the United Kingdom, and China to call for a "Summit on Human Gene Editing," which was held last December at the National Academies of Sciences, Engineering, and Medicine in Washington, D.C.
"Over the long term, CRISPRs could change the future of humanity, but no one is rushing into it," says Daniel Kevles, a historian of science at New York University Law School and Columbia University in New York, N.Y., and one of almost 500 experts who attended the summit. "Most of the participants welcomed the use of CRISPRs to treat diseases but strongly cautioned against germline editing, saying that it entails technical uncertainties and hazards to the offspring and also raises ethical issues."
"Just because we can speed ahead, doesn't mean we should," said another expert, George Church of Harvard Medical School in Boston, Mass.
Marcia Stone is a science journalist based in New
York City.
NEW FROM ASM
Visualizing Ebola Virus Fusion in Live Host Cells
There is a critical gap in understanding the events surrounding the fınal membrane fusion step of Ebola virus entry into its host cell. Kartik Chandran's group at Albert Einstein College of Medicine in the Bronx, N.Y., have addressed this gap by developing a real-time assay that allows visualization of this fınal step. The study, conducted by fırst author Jennifer Spence and published in mBio, uses vesicular stomatitis virus expressing the Ebola virus glycoprotein. The viral membranes are labeled with a lipophilic, self-quenching dye.
As the viral membranes fuse with the cell's unlabeled membranes, the dye's local concentration drops to release quenching, emitting a fluorescent flash that can be followed by microscopy in real time. Using this method, the team 150 • Microbe-Volume 11, Number 4, 2016 CURRENT TOPICS
